Mandlekar, Sandhya

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., et al. (2023) · New England Journal of Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 328

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 144

Considerations from an international regulatory and pharmaceutical industry (IQ MPS affiliate) workshop on the standardization of complex in vitro models in drug development

Tomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., Candarlioglu, P. L., Chan, T. S., Chen, E., Choi, C. K., et al. (2024) · Advanced Biology

3D Printing in Biomedical ResearchBiomedical Ethics and Regulation

Cited by 33

Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation

Desai, J., Han, S.-W., Lee, J.-S., Shacham-Shmueli, E., Massarelli, E., Cervantes, A., Garralda, E., Falcon, A., Miller, W. H., Gort, E., et al. (2023) · Cancer Research

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 10